JAMA Oncology

JAMA Oncology JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed publications.

Immune checkpoint inhibitor–induced occurred in 0.52% of patients across 158 National Cancer Institute trials, with hi...
12/27/2025

Immune checkpoint inhibitor–induced occurred in 0.52% of patients across 158 National Cancer Institute trials, with higher incidence for combination immunotherapy and lower rates when combined with . https://ja.ma/45ttFcm

A validated risk model accurately predicted 10-year risk of heart failure or cardiomyopathy in women treated for early-s...
12/27/2025

A validated risk model accurately predicted 10-year risk of heart failure or cardiomyopathy in women treated for early-stage breast cancer, integrating clinical and treatment variables available at diagnosis. https://ja.ma/496mbgA

The MyLungHealth randomized trial found that digital tools improved eligibility assessment and CT ordering for screeni...
12/26/2025

The MyLungHealth randomized trial found that digital tools improved eligibility assessment and CT ordering for screening, but gains in scan completion were limited. https://ja.ma/4srFCcG

Among over 7000 patients with , higher baseline fatigue before systemic therapy was linked to an increased risk of seve...
12/26/2025

Among over 7000 patients with , higher baseline fatigue before systemic therapy was linked to an increased risk of severe, life-threatening, and fatal adverse events. https://ja.ma/4b1CnCf

During nationwide platinum shortages, maintained overall platinum use for nonmetastatic lung cancer and substituted im...
12/25/2025

During nationwide platinum shortages, maintained overall platinum use for nonmetastatic lung cancer and substituted immunotherapy when treating metastatic cases, closely following national guidance. https://ja.ma/3Y6BiBE

Ductal carcinoma in situ (DCIS) score profiling after breast-saving surgery enabled selective radiotherapy, allowing hal...
12/23/2025

Ductal carcinoma in situ (DCIS) score profiling after breast-saving surgery enabled selective radiotherapy, allowing half of women with DCIS to safely avoid radiotherapy while maintaining low 5-year in-breast recurrence rates for all risk groups. https://ja.ma/498X8JW

Editorial: Cardiac surveillance recommendations after breast cancer treatment remain limited, with evidence suggesting m...
12/22/2025

Editorial: Cardiac surveillance recommendations after breast cancer treatment remain limited, with evidence suggesting most survivors benefit from primary care focused on prevention and management of traditional cardiovascular risk factors rather than routine long-term specialist surveillance. https://ja.ma/3Nb2SeA

Breast cancer risk for pathogenic variant carriers is substantially higher with a first-degree family history, and risk ...
12/22/2025

Breast cancer risk for pathogenic variant carriers is substantially higher with a first-degree family history, and risk estimates vary by gene, family history, and other factors, guiding personalized screening and prevention decisions. https://ja.ma/4p7p7PU

Head and neck is the seventh most common cancer worldwide. This JAMA Review summarizes the epidemiology, clinical pre...
12/21/2025

Head and neck is the seventh most common cancer worldwide.

This JAMA Review summarizes the epidemiology, clinical presentation, diagnosis, and treatment of head and neck squamous cell carcinomas ( ) of the upper aerodigestive tract.

https://ja.ma/3MOnF7G

Immune checkpoint inhibitors are independently linked to increased risk of Stevens-Johnson syndrome and toxic epidermal ...
12/21/2025

Immune checkpoint inhibitors are independently linked to increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis, with additive effects observed when combined with high-risk drugs. https://ja.ma/4j3yn6i

Address

330 N Wabash Avenue
Chicago, IL
60611

Telephone

+13126707827

Website

Alerts

Be the first to know and let us send you an email when JAMA Oncology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category